

Talking to Patients About MOUD

Thomas E. Freese, PhD
Co-Director, UCLA Integrated Substance Abuse Program

Gloria Miele, PhD
CA Hub and Spoke/UCLA ISAP

Monday, April 22nd, 2019



Disclosures

There are no relevant financial relationships with ACCME-defined commercial interests for anyone who was in control of the content of this activity.



Objectives

- ▶ Identify two (2) examples of stigmatizing language when talking about a substance use disorders.
- ▶ Describe three (3) reasons a patient might choose to start buprenorphine treatment.
- ▶ Demonstrate two (2) lessons learned from the clinical case presentation.

SUD Meets Criteria for Chronic Illness

- ▶ Common features with other chronic illnesses:
 - ▶ Heritability
 - ▶ Influenced by environment and behavior
 - ▶ Responds to appropriate treatment
 - ▶ Without adequate treatment can be progressive and result in substantial morbidity & mortality
 - ▶ Has a biological/physiological basis, is ongoing and long term, can involve recurrences

Source: <https://archives.drugabuse.gov/about/welcome/aboutdrugabuse/chronicdisease/de-long-term-lifestyle-modification>
<http://www.asam.org/quality-practice/definition-of-addiction>



The use of affirming language inspires hope and advances recovery.

LANGUAGE MATTERS.

Words have power.

PEOPLE FIRST.

The ATTC Network uses affirming language to promote the promises of recovery by advancing evidence-based and culturally informed practices.



ATTC

Addiction Technology Transfer Center Network
Funded by Substance Abuse and Mental Health Services Administration



University of California Los Angeles
Integrated Substance Abuse Programs

Person-First Language

Positive, Person-First Language	Stigmatizing Language
<ul style="list-style-type: none"> ● Person with a substance use disorder (SUD) ● Person who uses drugs (PWUD) ● Substance use / substance misuse ● Person in recovery 	<ul style="list-style-type: none"> ● Substance Abuse / Substance Abuser ● Addict, Alcoholic, Junkie ● Recovering “addict, alcoholic, substance abuser, junkie, etc.”
<ul style="list-style-type: none"> ● Person with justice-involvement; person that is justice-involved 	<ul style="list-style-type: none"> ● Criminal, Felon, Convict
<ul style="list-style-type: none"> ● Person experiencing homelessness 	<ul style="list-style-type: none"> ● Homeless
<ul style="list-style-type: none"> ● Positive / Negative 	<ul style="list-style-type: none"> ● Clean / Dirty
<ul style="list-style-type: none"> ● SUD / OUD pharmacotherapy ● Medications for addiction treatment 	<ul style="list-style-type: none"> ● Medication Assisted Treatment
<ul style="list-style-type: none"> ● Neonatal abstinence syndrome / Neonatal opioid withdrawal syndrome 	<ul style="list-style-type: none"> ● Addicted baby
<ul style="list-style-type: none"> ● Recurrence of use / recurrence of symptoms 	<ul style="list-style-type: none"> ● Relapse

<https://unityrecovery.org/person-first-pledge>



Talking to Patients about MOUD


The Essentials

- ▶ MOUD is standard of care for opioid use disorder
- ▶ Three FDA-approved medications
- ▶ Shared decision-making using motivational interviewing skills

Know the Medicines

- ▶ Buprenorphine
- ▶ Methadone
- ▶ Naltrexone

How Do Opioids Work?



Methadone



Dolophine[®] Methadose[®]



University of California Los Angeles
Integrated Substance Abuse Programs


Why Choose Methadone?

- ▶ Accessibility - Able to get to an approved program daily
- ▶ Pregnant and post-partum women
- ▶ Have severe or chronic pain
- ▶ People being treated for HIV/AIDS
- ▶ People who do best with structured programs
- ▶ Few long-term side effects
- ▶ Counseling promotes lifestyle changes



Buprenorphine

Buprenorphine/
Naloxone



Why choose buprenorphine?

- ▶ Best treated in doctors' offices
- ▶ Pregnant and postpartum women
- ▶ People being treated for HIV/AIDS
- ▶ Able to follow a treatment plan
- ▶ Motivated to try buprenorphine for MAT



Naltrexone



Why choose naltrexone?


- ▶ Able to stop using for 7-10 days
- ▶ Mandated by court or employer
- ▶ Comorbid alcohol problems
- ▶ Motivated to eliminate all opioids now
- ▶ Re-entering from prison or jail

Why choose no medication?



Shared Decision-Making Model

- ▶ Associated with better outcomes and patient satisfaction across medical care
- ▶ Patient-centered, non-hierarchical and collaborative approach



<https://store.samhsa.gov/product/Decisions-in-Recovery-Treatment-for-Opioid-Use-Disorders/SMA16-4993>



University of California Los Angeles
Integrated Substance Abuse Programs

What do you say when a patient asks...

“How long should I take buprenorphine?”



What do you say when a patient who has been taking buprenorphine for 90 days says....

“I think I’ve had enough treatment.
I’m ready to taper off.”



A MOUD patient who has been doing well on monthly office visits for 6 months is a no-show for a prescription appointment.

- ▶ What do you do?
- ▶ What do you say?
- ▶ What role does the MAT team play?

Summary

- ▶ Person-first language can reduce stigma and increase fact-based discussions about opioid use disorder
- ▶ Clinicians should be prepared to discuss the pros and cons of evidence-based treatments for OUD
- ▶ Using a shared decision-making model increases patient participation and engagement in treatment



Case Discussion

- ▶ What question do you have about a patient you are working with?



Join us for MAT ECHO 12-1pm, Fourth Monday of the Month

For more information or questions email:

Thomas E. Freese

tfreese@mednet.ucla.edu

Gloria Miele

gmiele@mednet.ucla.edu

To register, email

Kimberly Valencia

kimberlyvalencia@mednet.ucla.edu

